Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 4277551)

Published in Mol Med on November 18, 2014

Authors

Chiara Sonnino1, Sanah Christopher1, Claudia Oddi1, Stefano Toldo1, Raquel Appa Falcao1, Ryan D Melchior1, George H Mueller1, Nayef A Abouzaki1, Amit Varma1, Michael L Gambill1, Benjamin W Van Tassell1, Charles A Dinarello2, Antonio Abbate1

Author Affiliations

1: Virginia Commonwealth University, VCU Pauley Heart Center and Victoria Johnson Research Laboratories, Richmond, Virginia, United States of America.
2: Department of Medicine, University of Colorado, Aurora, Colorado, United States of America.

Associated clinical trials:

Anakinra to Prevent Adverse Post-infarction Remodeling (2) (VCU-ART2) | NCT01175018

NCT 01175018

Articles cited by this

Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57

Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature (1997) 10.53

Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40

Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34

Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem (1973) 8.51

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA (1994) 5.24

Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86

AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 4.19

Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13

The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73

Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab (2000) 3.42

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest (2000) 3.17

CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med (2007) 2.93

Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology (2006) 2.77

Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis (2001) 2.63

Targeting interleukin-1 in heart disease. Circulation (2013) 2.52

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation (2008) 2.23

Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology (2002) 2.04

Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology (2008) 1.92

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol (2010) 1.82

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A (2011) 1.81

Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res (2005) 1.81

Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J Physiol (2008) 1.80

C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J (2009) 1.79

Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70

An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology (2011) 1.60

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol (2013) 1.52

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care (2012) 1.46

Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol (1998) 1.39

Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest (2005) 1.33

Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology (2012) 1.26

The feeding of ethanol in liquid diets. Alcohol Clin Exp Res (1986) 1.25

The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology (1989) 1.24

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology (2002) 1.24

Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects. Dev Psychobiol (2006) 1.21

Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol (2014) 1.20

Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol (2004) 1.20

Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology (1993) 1.14

Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One (2010) 1.13

Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol (1991) 1.12

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One (2012) 1.08

Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology (2000) 1.08

Binge ethanol exposure increases liver injury in obese rats. Gastroenterology (2003) 1.08

CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med (2013) 1.06

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol (2013) 1.05

Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J (2006) 1.02

Pilot trials in clinical research: of what value are they? Circulation (2009) 0.99

Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res (2011) 0.96

Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol (2009) 0.92

A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function. J Biol Chem (2011) 0.90

Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Diabetologia (1995) 0.85

Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J Biol Chem (1987) 0.85

Endpoint colorimetric method for assaying total cholesterol in serum with cholesterol dehydrogenase. Clin Chem (1999) 0.83

M-30 and 4HNE are sequestered in different aggresomes in the same hepatocytes. Exp Mol Pathol (2007) 0.82

Long term intake of 0.1% ethanol decreases serum adiponectin by suppressing PPARγ expression via p38 MAPK pathway. Food Chem Toxicol (2014) 0.80

Targeting inflammation: impact on atherothrombosis. J Cardiovasc Transl Res (2013) 0.79

Nonalcoholic fatty liver disease. Curr Gastroenterol Rep (2000) 0.77

Gamma-Glutamyl-3-carboxy-14-nitroanilide: the substrate of choice for routine determinations of gamma-glutamyl-transferase activity in serum? Clin Chim Acta (1976) 0.77